X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SciTech's primary drug candidate, ST-001 (fenretinide), is currently undergoing Phase I clinical trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.
Lead Product(s): Fenretinide
Therapeutic Area: Oncology Product Name: ST-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
ST-001 (nanoFenretinide) is the patented formulation that enables the safe and rapid infusion of high-dose fenretinide, which is investigated for the treatment of cancer.
Lead Product(s): Fenretinide
Therapeutic Area: Oncology Product Name: ST-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
LAU-7b (oral fenretinide) is a novel candidate that acts on cell membrane lipids to modulate inflammation signaling and protein trafficking and is being investigated for the treatment of long COVID.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
LAU-7b (oral fenretinide) is a novel candidate that acts on cell membrane lipids to modulate inflammation signaling and protein trafficking. Fenretinide was shown to correct the levels of certain membrane phospholipids and sphingolipids in multiple in vitro and in vivo models.
Lead Product(s): Fenretinide
Therapeutic Area: Genetic Disease Product Name: LAU-7b
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
LAU-7b (Fenretinide) is a unique oral COVID-19 antiviral candidate with inflammation-controlling properties, with the potential to work on all mutations of COVID-19 and broader use in the hospital or at-home settings.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
LAU-7b was well-tolerated, with a safety profile comparable to the placebo arm and consistent with the existing safety data. The concomitant standard of care was evenly distributed among the treatment arms.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
LAU-7b was initially developed for its potential to trigger the resolution phase of inflammation, a natural mechanism that keeps the inflammatory response under control, without inducing immune-suppression (a “pro-resolving” effect).
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
Laurent Pharmaceuticals has decided to continue the study of its pro-resolving drug LAU-7b without modification in the Phase II RESOLUTION study in hospitalised Covid-19 patients.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
Laurent Pharmaceuticals today announced that it has received approval from the FDA to start enrolling U.S. patients in RESOLUTION, a multicentric Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential treatment against COVID-19 disease.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Fenretinide has demonstrated preclinical in-vitro antiviral activity against a number of viruses including MERs, Dengue, Zika, West Nile, HIV, and HCV.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
Details:
Laurent Pharmaceuticals is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
